SCHEMBL11900842

SCHEMBL11900842

CC[C@H](Nc1ncnc2c1ncn2C1CCCCO1)c1nc2ccc(F)cc2n1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ PIK3CG P48736 7/20 0.42
▸ PIK3CD O00329 6/20 0.42
▸ PIK3CA P42336 6/20 0.42
▸ PIK3CB P42338 6/20 0.42
▸ PIK3R1 P27986 4/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ CYP1A2 P05177 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ YTHDC1 Q96MU7 1/20 0.38
▸ PIK3R2 O00459 1/20 0.37
▸ ABCB11 O95342 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ PTGS1 P23219 1/20 0.37
▸ OPRM1 P35372 1/20 0.37
▸ PRKDC P78527 1/20 0.37
▸ SLC6A3 Q01959 1/20 0.37
▸ PDE4D Q08499 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11902085 0.91 PIK3CD (0.44) NPC1RAB9ASMN1; SMN2PIK3CGPIK3CD
SCHEMBL11901147 0.91 PIK3CD (0.53) NPC1RAB9ASMN1; SMN2PIK3CGPIK3CD
SCHEMBL15260579 0.84 PIK3CG (0.57) NPC1RAB9ASMN1; SMN2PIK3CGPIK3CD
SCHEMBL11900630 0.84 PIK3CD (0.53) NPC1RAB9ASMN1; SMN2PIK3CGPIK3CD
SCHEMBL11900905 0.83 NPC1 (0.62) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL1703383 0.82 NPC1 (0.49) NPC1RAB9ASMN1; SMN2PIK3CGPIK3CD
SCHEMBL12885795 0.81 PIK3CD (0.55) NPC1RAB9ASMN1; SMN2PIK3CGPIK3CD
SCHEMBL21980342 0.81 PIK3CD (0.54) NPC1RAB9ASMN1; SMN2PIK3CGPIK3CD
SCHEMBL12471910 0.81 NPC1 (0.55) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL21980237 0.80 PIK3CD (0.50) NPC1RAB9ASMN1; SMN2PIK3CGPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 — — US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 — — US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 — — US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 NPC1 941/4885RAB9A 2082/4885SMN1; SMN2 3302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback